Cargando…

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches

Detalles Bibliográficos
Autores principales:	Khan, Iftekhar, Baio, Gianluca, Ahmed, Saira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980284/ http://dx.doi.org/10.1186/1745-6215-14-S1-P119

Ejemplares similares

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Expected value of information in the case of mixed strategies
por: Baio, Gianluca
Publicado: (2013)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

Toxicité cutanée à l'erlotinib
por: Bourra, Hayat, et al.
Publicado: (2013)

Stability and Formulation of Erlotinib in Skin Creams
por: Nguyen, David, et al.
Publicado: (2022)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Directions vs. averages: an in-vivo comparison for cardiac DTI
por: Scott, Andrew D, et al.
Publicado: (2015)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer
por: Ciuleanu, Tudor-Eliade, et al.
Publicado: (2017)

Trichomegaly of Eyelashes after Treatment with Erlotinib in Carcinoma Pancreas
por: Goel, Varun, et al.
Publicado: (2014)

Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
por: Kim, En Hyung, et al.
Publicado: (2022)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

A Case of Cicatricial Alopecia Associated with Erlotinib
por: Yang, Bo Hee, et al.
Publicado: (2011)

Erlotinib hydrochloride: an anticancer agent
por: Selvanayagam, S., et al.
Publicado: (2008)

Acute Fatal Liver Toxicity under Erlotinib
por: Schacher-Kaufmann, Sabina, et al.
Publicado: (2010)

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma
por: ZHANG, HUAN-HUAN, et al.
Publicado: (2013)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
por: Garon, E.B., et al.
Publicado: (2023)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Comparison of automatic vs semiautomatic automated external defibrillators used by laypersons
por: Beckers, S, et al.
Publicado: (2004)

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
por: Nadal, Ernest, et al.
Publicado: (2021)

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
por: Hirte, Hal W
Publicado: (2013)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
por: Spitz, Kathleen E., et al.
Publicado: (2022)

A comparison of static vs dynamic surface topography measurements in the evaluation of scoliosis
por: Knott, P, et al.
Publicado: (2012)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Metformin and erlotinib synergize to inhibit basal breast cancer
por: Lau, Ying-Ka Ingar, et al.
Publicado: (2014)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o3c13gn3cq01lom0cpjv4dtkm9